VeraSIL Therapeutics, Inc., is a US based company with a focus on the IP development, technology transfer and licensing of a highly unique Nanomolecular technology that has been clinically demonstrated in a Phase 1 trial of 17 patients to extend the efficacy and stability of OnaBotolunimum Toxin A by upwards of 200% with zero adverse events reported. With the help of Mack Biotech, Inc, VeraSIL is currently pursuing a Phase 2 double blinded factorial clinical trial on 120 patients with this unique patent pending technology. This Phase 2 trial will compare the efficacy of BOTOX® reconstituted with saline to BOTOX® combined with Nanometallic Silver Tetraoxide using biometric EMG data to quantify /compare the length of muscle spasticity and relaxation. Dr Andrew Willoughby, the inventor of VeraSIL's technology, will discuss his Phase I clinical findings including the pharmacology and pharmacokinetics of this Bacteriostatic solution as well as proposed cellular mechanisms of action.